Leukocyte-poor platelet rich plasma

Biologic

QQueen Savang Vadhana Memorial Hospital, Thailand

Leukocyte-poor platelet rich plasma is one of 27 biologic programs targeting Osteoarthritis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteoarthritisActive, not recruiting

OsteoarthritisPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Toradol

Roche

Preclinical

1 2

Cataflam

Platelet Rich Plasma

25 4

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 5

Enbrel

IImmunex

Preclinical

2 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 7

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 8

Paracetamol

GSK

Preclinical

4 9

Naproxen Sodium

Bayer

Preclinical

1 10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteoarthritis2 trials

A Comparison of PRP Treatment to the IA vs. IA and EA Environments in Patients Diagnosed With Hip Osteoarthritis

Unknown status·RRegenerative Orthopedics and Sports Medicine·Phase 1·NCT04241354·84 enrolled

Intraarticular Leukocyte-rich and Leukocyte-poor PRP for Osteoarthritis of the Knee

Completed·QQueen Savang Vadhana Memorial Hospital, Thailand·Phase 2/3·NCT05737173·93 enrolled

ACL Reconstruction1 trial

Prospective Evaluation of PRP and BMC Treatment to Accelerate Healing After ACL Reconstruction

Active, not recruiting·SSteadman Philippon Research Institute·Phase 1/2·NCT04205656·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Leukocyte-poor platelet rich plasma. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Leukocyte-poor platelet rich plasma compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Leukocyte-poor platelet rich plasma. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Queen Savang Vadhana Memorial Hospital, Thailand company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: QQueen Savang Vadhana Memorial Hospital, Thailand

Leukocyte-poor platelet rich plasma

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteoarthritis2 trials

ACL Reconstruction1 trial

References

Drug Info

Quick Facts

Related News